Table 1.
Differentiated thyroid cancer incidence and pathological features in patients with and without autoimmune thyroid diseases
| Non-AITD | HT | GD | EHT | Hypo-HT | |
|---|---|---|---|---|---|
| DTC, n/total (%) | 600/1851 (32.4%) | 256/576 (44.4%) | 16/206 (7.8%) | 175/365 (47.9%) | 81/211 (38.4%) |
| OR vs. Non-AITD 95% CI P value | n/a | 1.67 1.38–2.02 < 0.0001 | 0.18 0.10–0.30 < 0.0001 | 1.92 1.53–2.41 < 0.0001 | 1.30 0.97–1.74 0.09 |
| Comparisons Between subgroups | n/a | OR = 0.11 95% CI = 0.06–0.18 p < 0.0001 | OR = 1.48 95%CI = 1.05–2.09 p = 0.029 | ||
| Size (cm) SEM | 1.8 (1.7) | 1.5 (1.3) | 0.7 (0.3) | 1.5 (1.2) | 1.5 (1.4) |
| p value compared to Non-AITD | n/a | 0.008 | < 0.001 | 0.029 | 0.062 |
| p value | n/a | 0.005 | 0.831 | ||
| Macro n (%) | 369 (66.4%) | 142 (55.9%) | 2 (12.5%) | 98 (56.9%) | 44 (57.8%) |
| OR vs. Non-AITD 95% CI p value | n/a | 1.56 1.15–2.11 0.005 | 13.8 3.11–61.4 < 0.001 | 1.49 1.05–2.11 0.028 | 1.44 0.84–2.34 0.158 |
| OR 95% CI p value | n/a | 8.88 1.98–39.9 0.001 | 0.96 0.56–1.66 1.000 | ||
| FTC n (%) | 46 (7.7%) | 12 (4.7%) | 0 0% | 9 (5.1%) | 3 (3.7%) |
| OR vs. Non-AITD 95% CI p value | n/a | 1.69 0.88–3.24 0.112 | 2.77 0.16–46.9 0.623 | 1.53 0.73–3.20 0.316 | 2.16 0.66–7.11 0.254 |
| OR 95% CI p value | n/a | 1.69 0.10–29.8 1.000 | 1.41 0.37–5.35 0.758 | ||
| FVPTC n (%) | 130 (21.7%) | 56 (21.9%) | 2 (12.5%) | 36 (20.6%) | 20 (24.7%) |
| OR vs. Non-AITD 95% CI p value | n/a | 0.99 0.69–1.41 1.000 | 1.94 0.43–8.63 0.542 | 1.07 0.71–1.62 0.834 | 0.84 0.49–1.45 0.568 |
| OR 95% CI p value | n/a | 1.96 0.43–8.88 0.535 | 0.79 0.42–1.48 0.516 | ||
| Other PTC variants n (%) | 12 (2.0%) | 10 (3.9%) | 0 0% | 4 (2.3%) | 6 (7.4%) |
Abbreviations: Non-AITD subjects without any form of autoimmune disease by pathology, HT subjects with Hashimoto’s thyroiditis, GD subjects with Graves’ disease, EHT subjects with Hashimoto’s thyroiditis by pathology and normal thyroid function, Hypo-HT subjects with hypothyroidism due to Hashimoto’s disease, Macro differentiated thyroid cancer larger than 1cm in maximum diameter, FVPTC follicular variant of papillary thyroid cancer, Other variants other forms of papillary thyroid cancer, i.e. oncocytic, solid, tall cell variants, Mets distant metastases, I-131 post-operative treatment with at least one dose of I-131
Comparison of thyroid cancer features with Fischer's exact test, between thyroid cancers found in the background of thyroid autoimmunity and those found in the absence of autoimmune thyroid diseases (Non-AITD). Odds ratios are reported as a comparison of the proportions between subjects with Non-AITD and subjects with autoimmune thyroid disorders
Odds ratios for the presence of DTC are estimated between subgroups of subjects with AITD and subjects without (Non-AITD). The odds ratios for DTC are estimated between different subgroups as well
Bold indicates a statistically significant difference between ratios